News & Updates
Filter by Specialty:
Teclistamab demonstrates clinical activity for R/R MM
The T-cell-redirecting bispecific antibody teclistamab induced deep and durable responses in patients with triple-class-exposed relapsed or refractory multiple myeloma (R/R MM), findings from the phase I/II MajesTEC-1 trial have shown.
Teclistamab demonstrates clinical activity for R/R MM
11 Aug 2022
Canagliflozin blunts end-stage renal disease risk in T2DM patients with CKD
In patients with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD), treatment with canagliflozin safely decreases the risk of developing end-stage renal disease, reports a new Japan study.
Canagliflozin blunts end-stage renal disease risk in T2DM patients with CKD
11 Aug 2022
1 week off methotrexate works okay for RA patients receiving flu shot
Temporarily discontinuing methotrexate treatment for 1 week appears to induce satisfactory response to a seasonal influenza vaccine in patients with rheumatoid arthritis (RA), with a similar effect as a 2-week interruption schedule, according to a study.
1 week off methotrexate works okay for RA patients receiving flu shot
11 Aug 2022
Men with PsA derive more benefit from MTX+ETN therapy than women
Combination therapy with methotrexate (MTX) plus etanercept (ETN) results in more improved outcomes in men than in women with psoriatic arthritis (PsA) for minimal disease activity (MDA) and Psoriatic Arthritis Disease Activity Score (PASDAS), a study has shown.